Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

Patent ExpiryATH434Positive

AI Analysis

Summary

Alterity Therapeutics announced the granting of a new U.S. Composition of Matter Patent for its drug candidate ATH434, strengthening intellectual property protection.

Outcome Details

New U.S. Composition of Matter Patent granted

Importance:3/10

Sentiment:

0.30

patentintellectual_propertyATH434

Related Companies

$ATHE

Read the original article

Published by yahoo_finance on August 12, 2026 11:05 AM

Read Original